Background: Short-chain fatty acids (SCFA) are microbial fermentation products ab-
| INTRODUCTION
The nature and composition of the gut microbiome is altered in a variety of diseases. Supplementation of specific beneficial bacteria termed probiotics or the alteration of gut microflora by non-absorbable antibiotics or by fecal transplantation from healthy subjects significantly improves inflammatory bowel disease, insulin sensitivity, and possibly irritable bowel syndrome (IBS). [1] [2] [3] [4] Although the pathogenesis of IBS has not been fully identified, gut microbial activity is likely related to symptom severity. As the colonic mucosa of IBS patients produces excitatory factors for cholinergic motor neurons and nociceptive neurons, [5] [6] [7] supraphysiologic activation of the enteric nervous system may in part underlie IBS symptoms.
Short-chain fatty acids (SCFA), such as acetate, propionate, and butyrate are key microbial products that interact with host cells. Up to 100 mM, SCFA are produced in the colonic lumen of non-ruminants by bacterial fermentation of dietary components that resist foregut digestion and absorption. 8, 9 In experimental rat IBS models, the supplementation of fermentable dietary fiber increases fecal SCFA content and prevents colonic transit acceleration under stressed conditions. 10 IBS patients have variable colonic SCFA content compared with healthy controls, independent of the predominant symptoms of constipation or diarrhea. 11, 12 As luminal SCFA are absorbed by colonic epithelial cells into the submucosa and the systemic circulation, Colonic peristalsis is regulated by enteric neural reflexes initiated by luminal pressure and chemicals, including SCFA that are well studied in vivo and in vitro. [18] [19] [20] When colonic muscle layers, including myenteric plexus, are isolated from the mucosa and submucosa, SCFA had no direct contractile effect on smooth muscle, 21 suggesting that the epithelial cells recognize SCFA and transduce signals to motor neurons that stimulate muscle contractions. In the same colonic muscle preparations, neurally activated muscle contractions are inhibited by SCFA, suggesting that myenteric neurons are directly influenced by SCFA during activation.
22
We recently reported that FFA3 is expressed on cholinergic nerves located in the mucosal and submucosal plexus of rat proximal colon, and that FFA3 activation suppressed nAChR-mediated anion secretion, possibly through the inhibition of neural ACh release. 
| MATERIALS AND METHODS

| Animals
Male Sprague-Dawley rats weighing 200-250 g (Harlan, San Diego, CA, USA) were fed a pellet diet and water ad libitum. All studies were performed with approval of the Veterans Affairs Institutional Animal
Care and Use Committee (protocol# 05007-16).
| Circular muscle contraction measurements
Rats were fasted overnight with free access to water before the experiments. Animals were euthanized by terminal exsanguination under deep isoflurane anesthesia, followed by thoracotomy. Segments of the proximal colon were removed and placed in cold Krebs-Ringer solution (pH 7.4), which consists of (in mmol L 
Key Points
• Short-chain fatty acids produced by the gut microbiota contribute to the colonic motility regulation in health and disease although the molecular mechanisms underlying this interaction are not fully understood.
• We identified the expression of a short-chain fatty acid receptor, free fatty acid receptor 3 (FFA3), in inhibitory and excitatory myenteric neurons. The activation of FFA3 suppressed nicotine-induced colonic contraction and relaxation ex vivo, and prevented serotonin-induced defecation in vivo.
• FFA3 is a promising target for treatment of neurogenic diarrhea.
after the equilibration period and by application of bethanechol (0.1 mM)
at the end of experiment. To determine the effects of test drugs on spontaneous contractions, we quantified the contraction frequency, mean peak amplitude, full-width half maximum (FWHM), and peak time (time between contraction peaks) of five peaks. Amplitude and FWHM of peak were determined for highdose nicotine-induced contraction, and peak time was determined for analyzing the relaxant effect of low-dose nicotine or serotonin. When test drugs suppressed basal contractions, the peak time was determined as the time between the last peak before drug application and the first peak after drug application with >50% extent of prior peak.
| Immunohistochemistry
Overnight fasted rats underwent transcardiac perfusion with saline followed by 4% paraformaldehyde in phosphate buffered saline (PBS, ) was raised using recombinant C-terminal 28 amino acids of rat FFA3 (RAC VPWTQ EVSLE LKVKN GEEPS KECPS); antibody specificity was confirmed in a previous study. 23 The sections were then washed, incubated with fluorescent-conjugated secondary antibodies (1:500, 2 h, room temperature; Molecular Probes, Eugene, OR, USA), and covered with EverBrite mounting medium with 4′,6-diamidino-2-phenylindole (DAPI;
Biotium, Hayward, CA, USA). Immunofluorescence was imaged and captured using a confocal laser microscope (LSM710; Carl Zeiss GmbH, Jena, Germany).
| Defecation model in vivo
Prior the experimental day, rats were acclimated to wire-mesh floored cages. On the experimental day at 0900, non-fasted rats were given saline-diluted AR420626 (0.1 mg kg 
| Chemicals
hexahydro-quinoline-3-carboxamide (MQC) 24 was synthesized, purified and verified in Laboratory of Organic Chemistry, School of Pharmaceutical Sciences, University of Shizuoka, Japan. AR420626
was purchased from Cayman Chemical (Ann Arbor, MI, USA).
AR420626 is a selective agonist of FFA3 (IC 50 =117 nM on cAMP content) that does not activate the related receptor FFA2 (GPR43) at concentrations up to 100 μM. 25 GR113808 and PTX were purchased from Tocris Bioscience (Pittsburgh, PA, USA). Atropine, bethanechol, hexamethonium, serotonin, TTX, IND, nicotine, L-NAME, ondansetron, granisetron, and other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). IND was dissolved in 100% ethyl alcohol; TTX, nicotine, bethanechol, PTX, and L-NAME were dissolved in distilled water, and other chemicals were dissolved in dimethyl sulfoxide.
| Statistical analysis
Values were expressed as mean±SEM. Statistical analysis was performed using Prism ver. 6 (GraphPad Software Inc., La Jolla, CA, USA).
For multiple comparisons of >3 groups, one-way ANOVA was used for directly measured parameters, whereas the Kruskal-Wallis test was used for results expressed as ratios with P<.05 considered statistically significant. All authors had access to the study data and reviewed and approved the final manuscript.
| RESULTS
| Effect of FFA3 agonists on spontaneous contractions in circular muscle strips of rat proximal colon
In order to examine the effects of FFA3 activation on myenteric neurons, we chose to study isolated muscle preparations including myenteric plexus, which eliminate the influences of the FFA3-expressing submucosal plexus and mucosal enteroendocrine cells. 23 Strips of proximal colon circular muscle spontaneously generated constant contractions with two large-amplitude spikes/min that started within 45 min after mounting the preparation ( Figure 1A ). The frequency of spontaneous contractions was increased by treatment with the cyclooxygenase inhibitor IND or the NOS inhibitor L-NAME, but was not altered by TTX, signifying that spontaneous contractions of circular muscle in this experimental system are inhibited by endogenously generated prostaglandins (PGs) and by NO release ( Figure 1B) . None of these treatments significantly changed the mean amplitude of spontaneous contractions ( Figure 1C ).
The time course of repeated waveforms is defined by FWHM and peak time. Mean FWHM was not altered by any drug treatment ( Figure 1D ), whereas peak time was decreased by IND, TTX, or L-NAME ( Figure 1E ), indicating that the interval of spontaneous contraction was shortened without alteration of each contractile peak form. Although peak time is a reciprocal value of Hz and inversely correlated with frequency, peak time was preferred for statistical analysis among the groups.
| Effect of a FFA3 agonist on high-dose nicotine-induced contractions
Application of 100 μM nicotine into the organ bath immediately and strongly contracted the circular muscle strip followed by transient 2E ). The effect of AR420626 was more potent than that of MQC, and was reversed by pretreatment with the G i/o inhibitor PTX ( Figure 2E ).
These results suggest that FFA3 activation may suppress ACh release through G i/o activation at the nerve terminals innervating circular muscles.
| Effect of FFA3 agonists on low-dose nicotine-induced relaxation
The spontaneous contractions of circular muscle were transiently silenced and recovered without alteration of basal tone by the addition of 10 μM nicotine into the organ bath ( Figure 3A ). This response was inhibited by TTX or L-NAME, indicating that this concentration of 
| Effect of FFA3 agonists on serotonininduced relaxation
In order to confirm the involvement of serotonergic pathway in the inhibitory response to low-dose nicotine, the effect of serotonin was examined in the presence of IND. The application of serotonin (100 μM) into the organ bath immediately contracted proximal colon circular muscle strips followed by transient inhibition of spontaneous contractions ( Figure 4A ). The first peak after serotonin application was not changed by L-NAME, AR420626 (10 μM), or granisetron (10 μM) ( Figure 4B ), whereas the peak time induced by serotonin was significantly reduced by L-NAME, AR420626, or granisetron ( Figure 4C ).
These data suggest that serotonin stimulates NO release through 5-HT 3 activation, inhibiting circular muscle contraction, and that FFA3 activation reverses the serotonin-evoked NO-mediating circular muscle relaxation.
| Effect of FFA3 agonists on bethanecholinduced contractions
The muscarinic ACh receptor agonist bethanechol immediately in- 
| Effect of FFA3 agonist AR420626 on exogenous serotonin-induced defecation in vivo
As 5-HT 3 receptor antagonists are therapeutic for IBS-D, 28 we tested the effect of the potent FFA3 agonist AR420626 on serotonininduced defecation model. 29 Intraperitoneal serotonin injection Although pretreatment with AR420626 alone had no effect on defecation, AR420626 significantly inhibited serotonin-induced fecal output. 
| FFA3 localization in enteric neurons and intramuscular nerves
We previously reported that FFA3 immunoreactivity was localized to a subset of myenteric neurons and nerves in whole mount preparations of rat proximal colon. 23 In the present study, we found that intramuscular nerve fibers running along the long axis of smooth muscle cells as well as myenteric neurons co-expressed FFA3 and nNOS ( Figure 7) . Almost all PGP9.5-positive intramuscular nerve fibers expressed nNOS, indicating that inhibitory motor neurons innervate the muscle layers and release NO at the connections with smooth muscle cells (Figure 7) . In contrast to the myenteric plexus, nNOS did not typically colocalize 
| DISCUSSION
We demonstrated that FFA3 activation inhibited nicotine-evoked neural activity in the regulation of colonic motility, extending our prior observations that FFA3 was localized on cholinergic nerves in the mucosal and submucosal plexuses, and that FFA3 activation suppressed nicotine-evoked neurogenic anion secretion via activation of the inhibitory G i/o pathway. 23 In mucosa-free circular muscle strips, both NO-mediated relaxation and ACh-mediated contractions were F I G U R E 8 Immunohistochemistry of cholinergic neurons in proximal colonic sections. Immunoreactivities of FFA3 (green) and a cholinergic neural marker VAChT (red) were identified in intramuscular nerves and myenteric plexus. Colocalization was indicated by arrows (yellow). Arrowheads represent the lack of colocalization. Bar: 20 μm.
F I G U R E 9
Confocal microscopy with z-stack imaging demonstrating colocalization of FFA3 and cholinergic (ChAT) or nitrergic (nNOS) neural markers in intramuscular nerve fibers in proximal colonic thick sections. The upper three panels depict 3D image whereas the bottom panels depict a confocal image demonstrating the coincidence of green-labeled FFA3 and red-labeled neural marker in varicosities appearing as a yellow color (arrows). Arrowheads indicate lack of colocalization. Bar: 5 μm.
suppressed by FFA3 agonists, consistent with the immunohistochemical finding that FFA3 is expressed on intramuscular varicosities of nitrergic (inhibitory) and cholinergic nerves and on these neurons.
Furthermore, a selective and potent FFA3 agonist prevented exogenous serotonin-induced circular muscle relaxation ex vivo and defecation in vivo, emphasizing the therapeutic potential of FFA3 agonists as antidiarrheal drugs.
| FFA3 localization in myenteric plexus
ACh and NO are primary transmitters of excitatory and inhibitory enteric motor neurons, respectively. 30 In the myenteric plexus and intramuscular nerve fibers, FFA3 was expressed in cholinergic and nitrergic nerves, in contrast to the mucosal and submucosal plexuses, where FFA3 was localized mostly in cholinergic nerves. 
| FFA3 function in nAChR-mediated colonic motility regulation
Vagal excitation and exogenous nicotine activate nAChRs located on numerous postsynaptic neurons, which may release ACh or NO, triggering muscle contraction or relaxation, respectively. 
| Are enteric neurons physiologically suppressed by FFA3 activation?
The present study demonstrated that FFA3 was localized to myen- implicating that these animal models in some ways resemble IBS-D.
In the present study, the potent FFA3 agonist AR420626 prevented serotonin-induced circular muscle relaxation ex vivo and defecation in vivo. Although it is difficult to explain serotonin-evoked peristalsis solely on results derived from ex vivo experiments, circular muscle relaxation occurring together with longitudinal contraction 46 in the proximal colon may be a local mechanism by which serotonin evokes the defecatory reflex. In light of these experimental studies, orally active FFA3 agonists that target enteric nerves may be useful therapeutically for IBS or other neurogenic functional disorders.
The present study and our prior studies documented that FFA3
was localized on enteric nerves and that FFA3 activation inhibits colonic secretion and motility initiated by nAChR activation. 
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